Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after ...

Emkay Global Financial is bearish on Dr Reddys recommended sell rating on the stock with a target price of Rs 1150 in its ...

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Extending losses for the second session, Dr Reddy’s shares dropped 6.65% to hit a low of ₹1,203.60 on the BSE as investors weighed weak Q3 results.

For instance, ferumoxytol and ferric carboxymaltose had lower rates of adverse reactions compared to iron sucrose and iron dextran [2]. Additionally, a randomized trial highlighted that ferric ...

As many as 38 drug samples manufactured in various drug clusters of the state failed quality parameters in the monthly alert ...

New Delhi: In line with the 'Not of Standard Quality' data provided by states, the apex drug regulatory body, the Central ...

Dr. Reddy's shares are the top losers on the Nifty 50 index today. Out of the 40 analysts that have coverage on Dr. Reddy's, ...

Check out the latest brokerage calls and analyst comments on the stocks in action today. Our coverage includes HPCL, Indus ...

Ladies and gentlemen, good day and welcome to the Quarter Three FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only ...

Anemia of cancer is characterized by ineffective erythropoiesis, which is due to a number of factors. One of the most important among these is abnormal iron metabolism. Iron deficiency can occur ...

8316.T Sumitomo Mitsui Financial Group, Inc.